Modelling the Effect of SPION Size in a Stent Assisted Magnetic Drug Targeting System with Interparticle Interactions

Adil Mardinoglu¹ and P. J. Cregg²

¹Department of Biology and Biological Engineering, Chalmers University of Technology, 412 96 Gothenburg, Sweden
²Materials Characterisation & Processing Group, Waterford Institute of Technology, Waterford, Ireland

Correspondence should be addressed to Adil Mardinoglu; adilm@chalmers.se

Received 28 September 2014; Accepted 1 February 2015

Abstract

Cancer is a leading cause of death worldwide and it is caused by the interaction of genomic, environmental, and lifestyle factors [1]. Although chemotherapy is one way of treating cancers, it also damages healthy cells and may cause severe side effects. Therefore, it is beneficial in drug delivery in the human body to increase the proportion of the drugs at the target site while limiting its exposure at the rest of body through Magnetic Drug Targeting (MDT). Superparamagnetic iron oxide nanoparticles (SPIONs) are derived from polyol methods and coated with oleic acid and can be used as magnetic drug carrier particles (MDCPs) in an MDT system. Here, we develop a mathematical model for studying the interactions between the MDCPs enriched with three different diameters of SPIONs (6.6, 11.6, and 17.8 nm) in the MDT system with an implanted magnetizable stent using different magnetic field strengths and blood velocities. Our computational analysis allows for the optimal design of the SPIONs enriched MDCPs to be used in clinical applications.

1. Introduction

Cancer is a leading cause of death worldwide. Its cause is multifactorial and is linked to the interaction of genomic, environmental, and lifestyle factors [1]. Cancer patients are often diagnosed with localized reduction or loss of cellular control and normal maturation mechanisms that incorporate excessive cell growth, loss of cell differentiation, and the ability of cancerous tissue to grow into neighbouring tissues [2, 3]. Chemotherapy is one type of cancer treatment that inhibits the growth of, or kills, tumours. However, chemotherapy can damage healthy cells in the human body and it has many undesirable side effects [4]. It is therefore beneficial to alter the distribution of drugs in the human body, increasing the proportion of drugs at the target site while limiting concentration and effects in the rest of body through the use of Magnetic Drug Targeting (MDT) [5, 6]. Similar techniques have also been used to deliver other agents including cells [7].

MDT refers to the attachment of therapeutics to magnetizable particles to concentrate them at the desired locations by applying magnetic fields [8]. It includes the investigation of an external magnetic field and its interaction with biocompatible magnetic drug carrier particles (MDCPs) [9]. Significant difficulties in MDT are the inherently weak magnetic force relative to the hydrodynamic forces and targeting zones deep below the skin [10, 11]. This makes MDCP collection problematic, because the magnetic force on a MDCP is proportional not only to the magnitude of the magnetic field but also to its gradient. To overcome these limitations, soft ferromagnetic materials such as wires, seeds, and stents are implanted into the body to increase the localized magnetic field strength and gradient, and this technique is called Implant Assisted Magnetic Drug Targeting (IA-MDT) [12–15]. Different theoretical and clinical applications of IA-MDT have been developed [16–23]. Moreover, an IA-MDT system which uses a magnetizable stent as an implant and high gradient magnetic separation (HGMS) in a physiologically stretched vessel was studied with a 2D mathematical model [24]. In this Stent Assisted Magnetic Drug Targeting (SA-MDT) system, a ferromagnetic stent was implanted to aid
collection of MDCPs in an elastic tube that has similar mechanical properties to the blood vessel and the changes in the mechanical behaviour were analyzed under the influence of mechanical forces generated.

There has been a growing interest in the scientific and clinical application of MDCPs as MDT vehicles for the development of efficient treatment strategies. A nanoparticle-based cancer drug has been developed and the phase I clinical study of cancer patients providing positive clinical evidence for the progress of nanoparticle application is reported [25]. The scientific world journal has presented the next experimental challenge to develop a clinically relevant SA-MDT system. We model the behaviour of N MDCPs under the influence of (i) Stokes drag, (ii) hydrodynamic interaction forces, and (iii) magnetic forces that account for the mutual magnetic dipole-dipole interactions and calculated (iv) the velocity of each MDCP and MDCP $n$ and (v) the system performance in terms of collection efficiency (CE) ignoring the effect of inertia and gravity (Figure 1).

The forces acting on a given particle labeled $n$ MDCP $n$ are calculated as follows.

(i) Stokes drag, $\vec{F}_\text{stokes}$, decreases the blood velocity relative to the MDCPs and it can be written as

$$\vec{F}_\text{stokes} = 6\pi \eta \text{blood} R_{p_n} (\vec{v}_\text{blood} - \vec{v}_{p_n}),$$

where $\eta \text{blood}$ is the viscosity of the blood, $R_{p_n}$ is the radius of MDCP $n$, and $\vec{v}_\text{blood}$ and $\vec{v}_{p_n}$ are the velocities of the blood and MDCP $n$, respectively. In the model, $\vec{v}_\text{blood}$ is determined by solving the appropriate Navier–Stokes equations as previously described [15].

(ii) Hydrodynamic interaction force, $\vec{F}_\text{hydro}$, is determined as the disturbance of the MDCP $n$ due to the movement of other MDCPs in the blood flow. By considering $N$ MDCPs, the force acting on MDCP $n$ due to the presence of the other $(N-1)$ MDCPs is given by

$$\vec{F}_\text{hydro} = \sum_{i=1}^{N} \xi_{ni} \cdot (\vec{v}_\text{blood} - \vec{v}_i),$$

where $\vec{v}_i$ is the velocity of MDCP $i$ and $\xi_{ni}$ is the modification due to the hydrodynamic interaction.

(iii) Magnetic forces acting on MDCP $n$, $\vec{F}_\text{magnetic}$, account for the externally applied magnetic field strength and mutual magnetic dipole-dipole interactions between MDCPs. Considering the $N$ MDCPs, each MDCP is taken as spherical and is having a homogeneous magnetic flux throughout the entire volume. $\vec{F}_\text{magnetic}$ on MDCP $n$ can be written as

$$\vec{F}_\text{magnetic} = (\vec{m}_n \cdot \nabla) \vec{B}_{\text{Total} n},$$

where $\vec{m}_n$ is the total magnetic moment of MDCP $n$ and $\vec{B}_{\text{Total} n}$ is the total magnetic flux acting on MDCP $n$.

(iv) The velocity of MDCP $n$, $\vec{v}_{p_n}$, is obtained by summing the Stokes drag, the force due to hydrodynamic interaction, and the modified magnetic force (ignoring the inertial forces) as

$$6\pi \eta \text{blood} R_{p_n} (\vec{v}_\text{blood} - \vec{v}_{p_n}) + \sum_{i=1}^{N} \xi_{ni} \cdot (\vec{v}_\text{blood} - \vec{v}_i) + (\vec{m}_n \cdot \nabla) \vec{B}_{\text{Total} n} = 0.$$
The system performance of the model is calculated in terms of collection efficiency (CE) and the trajectories of MDCP are obtained from evaluating the streamline functions. Consider

\[ CE = \frac{2R_{\text{vessel}} - y_1 + y_2}{2R_{\text{vessel}}} \times 100\% \]  

where \( R_{\text{vessel}} \) is the radius of the vessel and \( y_1 \) and \( y_2 \) are defined by the location of the streamline at the entrance of control volume (CV) of the last MDCPs captured by the stent wires.

### 3. Results

In the current study, we present the simulation results of the behaviour of MDCPs enriched with three different sizes of SPIONs (diameters 6.6, 11.6, and 17.8 nm) in SA-MDT system. We examine the effects of interactions on the CE of the system in terms of the changes in blood velocity and applied magnetic field strength (Table 2).

We calculate the forces due to the magnetic dipole-dipole and hydrodynamic interactions on \( N = 100 \) MDCPs together with the blood flow velocity. Magnetic and hydrodynamic forces acting on MDCPs as well as blood velocity were calculated using the finite volume library OpenFOAM [29]. We create a homogeneously distributed square cloud of 100 MDCPs at the entrance of the CV, place the centre of the cloud at boundary of the reference capture cross section, simulate the behaviour of MDCPs at every time step considering their agglomeration, and eventually obtain the altered trajectories of MDCPs for calculating the CE. The number of the MDCPs is limited to 100 and the effective initial distance between the MDCPs at the entrance of CV is presented in Table 2 as calculated from a previous experimental setup [18]. In our previous studies, the number of MDCPs in the simulations has been limited to 25 leading to close agreement with the experimental results [18].

In order to describe the effect of different SPION diameter on the content of MDCPs, \( \vec{F}_{mm} \) is calculated at the entrance of CV for each MDCP and presented in Figure 2. The saturation magnetization of SPIONs (oleate-capped, Fe\(_3\)O\(_4\) nanoparticles) [28] is presented in Table 1. The number of the SPIONs in MDCP is inversely proportional to the diameter of the SPIONs. Improving the content and structure of the MDCPs and having better surface to volume ratio, we can have better applications of MDCPs in clinical studies.

Figure 2 shows the variation in CE of the SA-MDT system at four different applied magnetic field strengths (0.25, 0.50, 0.75, and 1 T) and four different injection fluid velocities (0.05, 0.1, 0.25, and 0.5 cm/s). The resulting collection efficiencies derived from this mathematical model are in agreement with previously published work [18], and with differing SPION diameter, the system performance can differ by up to 20% in absolute terms.

### 4. Discussions

We have presented SA-MTD model incorporating the agglomeration of particles known to occur in real biological
| Properties                              | Symbol | Units      | Values           |
|----------------------------------------|--------|-----------|------------------|
| **Applied field properties**           |        |           |                  |
| Magnitude                              | \( \mu_0 H_0 \) | T          | 0.25, 0.50, 0.75, 1 |
| Angle of field direction               | \( \theta \) | —         | \( \pi/2 \)       |
| **Physical properties**                |        |           |                  |
| Temperature                            | \( T \) | K         | 300              |
| Boltzmann's constant                   | \( k_B \) | J/K       | \( 1.38 \times 10^{23} \) |
| Permeability of vacuum                 | \( \mu_0 \) | Tm/A      | \( 4\pi \times 10^{-7} \) |
| **MDCPs properties**                  |        |           |                  |
| Polymer material                       | —      | —         | P(S/V-COOH)Mag   |
| Radius                                 | \( R_p \) | \( \mu \) m | 0.5              |
| MDCP concentration                     | —      | Particle/L | \( 4 \times 10^{10} \) |
| Density of the polymer material        | \( p_{pol,p} \) | kg/m³ | 950              |
| Initial distance between MDCPs         | —      | \( \mu \) m | 29.24            |
| Saturation magnetization               | \( M_{p,s} \) | kA/m     | 22.4             |
| **Stent properties**                   |        |           |                  |
| Material                               | —      | —         | SS 430           |
| Wire radius                            | \( R_{wire} \) | \( \mu \) m | 62.5             |
| Loop separation                        | \( H \) | cm        | 0.2              |
| Number of loops                        | \( N_l \) | —         | 10               |
| Coil length                            | \( L \) | cm        | 2                |
| Saturation magnetization               | \( M_{implant,s} \) | kA/m | 1261             |
| Magnetic susceptibility                 | \( X_{implant,0} \) | —         | 1000             |
| **Blood and vessel properties**        |        |           |                  |
| Velocity                               | \( u_0 \) | cm/s      | 0.05, 0.1, 0.25, 0.5 |
| Volume                                 | \( V_{blood} \) | mL | 10               |
| Density                                | \( \rho_b \) | kg/m³ | 1000             |
| Viscosity                              | \( \eta_b \) | kg/ms | \( 1.0 \times 10^{-3} \) |
| Vessel radius                          | \( R_{vessel} \) | cm | 0.05             |
| **Magnetic material properties**       |        |           |                  |
| Material                               | —      | —         | Oleate-capped Fe_3O_4 |
| Weight content                         | \( X_{fm,p} \) | wt% | 100              |
| Density                                | \( \rho_{fm,p} \) | kg/m³ | 5000             |
| Magnetic moment                        | \( m_{fm,p} \) | Am² | —                |
| Saturation magnetization               | \( M_{fm,p,s} \) | kA/m | See Table 1      |
| Diameter                               | \( R_{fm,p} \) | nm | —                |

We envisage that new insights obtained from the results of our analysis may be used in prediction of efficacy of targeted drug delivery for designing effective nanotherapeutic tools that can translate into the clinic. The CE of the system is increased with the higher magnetic field strength and decreased with the higher blood velocities as expected. Moreover, the modelling of different sizes of SPIONs in a SA-MDT system presented in this work represents a useful analytical tool for the prediction of the efficacy of targeted drug delivery. Our simulations indicate that size of the SPIONs in MDCPs together with saturation magnetization of the SPIONs has considerable effect on collection efficiency of the SA-MDT system. The response of SA-MDT is mainly dominated by the size of SPIONs and the saturation magnetization value of SPIONs, and these parameters can be calibrated based on the clinical applications of SA-MDT system using the results of our simulation. Improvement of the fundamental models in MDT systems may allow for the development of the more complex models that include systems level interactions.

The presented mathematical model for the movement of the MDCPs in the blood can be integrated with genome-scale metabolic models (GEMs) for healthy cells/tissues [30–33], cancers [34, 35], and cancer cell lines [36]. GEMs are
Figure 2: CE of the SA-MDT system is plotted with different magnetic field strengths (0.25, 0.50, 0.75, and 1T) and blood velocities (0.05, 0.1, 0.25, and 0.5 cm/s).

The compilation of biochemical reactions to define the entire known metabolism of the cells and tissues [37, 38], and they are reconstructed through the integration of proteomics [33, 39], transcriptomics [40–42], and metabolomics data [43]. Such integrative models can be used for discovery of novel biomarkers as well as for identification of drug targets to develop efficient treatment strategies for metabolism related diseases including cancer [44].

Conflict of Interests

The authors declare that they have no conflict of interests.

Acknowledgments

Dr. Adil Mardinoglu would like to thank the Knut and Alice Wallenberg Foundation and Dr. P. J. Cregg would like to thank Enterprise Ireland and the School of Engineering, WIT, for financial assistance to attend the 10th International Conference on the Clinical Applications of Magnetic Carriers, in Dresden, 2014. The authors would like to thank Dr. Adriele Prina-Mello for his comments and suggestions about the work.

References

[1] D. Hanahan and R. A. Weinberg, “Hallmarks of cancer: the next generation,” Cell, vol. 144, no. 5, pp. 646–674, 2011.
[2] M. G. Vander Heiden, “Targeting cancer metabolism: a therapeutic window opens,” Nature Reviews Drug Discovery, vol. 10, no. 9, pp. 671–684, 2011.
[3] D. A. Tennant, R. V. Durán, and E. Gottlieb, “Targeting metabolic transformation for cancer therapy,” Nature Reviews Cancer, vol. 10, no. 4, pp. 267–277, 2010.
[4] S. H. Kaufmann and W. C. Earnshaw, “Induction of apoptosis by cancer chemotherapy,” Experimental Cell Research, vol. 256, no. 1, pp. 42–49, 2000.
The Scientific World Journal

by a magnetizable intravascular stent—2: parametric study with multi-wire two-dimensional model, Journal of Magnetism and Magnetic Materials, vol. 293, no. 1, pp. 616–632, 2005.

[21] M. O. Avilés, A. D. Ebner, and J. A. Ritter, “Ferromagnetic seeding for the magnetic targeting of drugs and radiation in capillary beds,” Journal of Magnetism and Magnetic Materials, vol. 310, no. 1, pp. 131–144, 2007.

[22] M. O. Avilés, A. D. Ebner, and J. A. Ritter, “Implant assisted-magnetic drug targeting: comparison of in vitro experiments with theory,” Journal of Magnetism and Magnetic Materials, vol. 320, no. 21, pp. 2704–2713, 2008.

[23] J. O. Mangual, M. O. Avilés, A. D. Ebner, and J. A. Ritter, “In vitro study of magnetic nanoparticles as the implant for implant assisted magnetic drug targeting,” Journal of Magnetism and Magnetic Materials, vol. 323, no. 14, pp. 1903–1908, 2011.

[24] A. Mardinoglu, P. J. Cregg, K. Murphy, M. Curtin, and A. Prina-Mello, “Theoretical modelling of physiologically stretched vessel in magnetisable stent assisted magnetic drug targeting application,” Journal of Magnetism and Magnetic Materials, vol. 323, no. 3-4, pp. 324–329, 2011.

[25] C. Sheridan, “Proof of concept for next-generation nanoparticle drugs in humans,” Nature Biotechnology, vol. 30, no. 6, pp. 471–473, 2012.

[26] J.-H. Lee, B. Schneider, E. K. Jordan, W. Liu, and J. A. Frank, “Synthesis of complexable fluorescent superparamagnetic iron oxide nanoparticles (FL SPIONs) and cell labeling for clinical application,” Advanced Materials, vol. 20, no. 13, pp. 2512–2516, 2008.

[27] I. J. M. de Vries, W. J. Lasterhuis, J. O. Barentsz et al., “Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy,” Nature Biotechnology, vol. 23, no. 11, pp. 1407–1413, 2005.

[28] D. Caruntu, G. Caruntu, and C. J. O’Connor, “Magnetic properties of variable-sized Fe₃O₄ nanoparticles synthesized from non-aqueous homogeneous solutions of polyols,” Journal of Physics D: Applied Physics, vol. 40, no. 19, pp. 5801–5809, 2007.

[29] H. Jasak, “OpenFOAM: open source CFD in research and industry,” International Journal of Naval Architecture and Ocean Engineering, vol. 1, no. 2, pp. 89–94, 2009.

[30] A. Mardinoglu, R. Agren, C. Kampf et al., “Integration of clinical data with a genome-scale metabolic model of the human adipocyte,” Molecular Systems Biology, vol. 9, article 649, 2013.

[31] A. Mardinoglu, R. Agren, C. Kampf, A. Asplund, M. Uhlen, and J. Nielsen, “Genome-scale metabolic modelling of hepatocytes reveals serine deficiency in patients with non-alcoholic fatty liver disease,” Nature Communications, vol. 5, article 3083, 2014.

[32] A. Mardinoglu, C. Kampf, A. Asplund et al., “Defining the human adipose tissue proteome to reveal metabolic alterations in obesity,” Journal of Proteome Research, vol. 13, no. 11, pp. 5106–5119, 2014.

[33] M. Uhlen, L. Fagerberg, B. M. Hallstrom et al., “Tissue-based map of the human proteome,” Science, vol. 347, Article ID 1260419, 2015.

[34] R. Agren, S. Bordel, A. Mardinoglu, N. Poraputtapong, I. Nookaew, and J. Nielsen, “Reconstruction of genome-scale active metabolic networks for 69 human cell types and 16 cancer types using INIT,” PLoS Computational Biology, vol. 8, no. 5, Article ID e1002518, 2012.

[35] R. Agren, A. Mardinoglu, A. Asplund, C. Kampf, M. Uhlen, and J. Nielsen, “Identification of anticancer drugs for hepatocellular carcinoma through personalized genome-scale metabolic
modeling,” *Molecular Systems Biology*, vol. 10, no. 3, article A721, 2014.

[36] P. Ghaffari, A. Mardinoglu, A. Asplund et al., "Identifying anti-growth factors for human cancer cell lines through genome-scale metabolic modeling," *Scientific Reports*, vol. 5, article 8183, 2015.

[37] A. Mardinoglu, F. Gatto, and J. Nielsen, “Genome-scale modeling of human metabolism—a systems biology approach,” *Biotechnology Journal*, vol. 8, no. 9, pp. 985–996, 2013.

[38] A. Mardinoglu and J. Nielsen, “Systems medicine and metabolic modelling,” *Journal of Internal Medicine*, vol. 271, no. 2, pp. 142–154, 2012.

[39] M. Uhlen, P. Oksvold, L. Fagerberg et al., “Towards a knowledge-based Human Protein Atlas,” *Nature Biotechnology*, vol. 28, no. 12, pp. 1248–1250, 2010.

[40] C. Kampf, A. Mardinoglu, L. Fagerberg et al., “The human liver-specific proteome defined by transcriptomics and antibody-based profiling,” *The FASEB Journal*, vol. 28, no. 7, pp. 2901–2914, 2014.

[41] C. Kampf, A. Mardinoglu, L. Fagerberg et al., "Defining the human gallbladder proteome by transcriptomics and affinity proteomics," *Proteomics*, vol. 14, no. 21-22, pp. 2498–2507, 2014.

[42] L. Fagerberg, B. M. Hallstrom, P. Oksvold et al., “Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics,” *Molecular and Cellular Proteomics*, vol. 13, no. 2, pp. 397–406, 2014.

[43] D. S. Wishart, C. Knox, A. C. Guo et al., "HMDB: a knowledge-base for the human metabolome," *Nucleic Acids Research*, vol. 37, supplement 1, pp. D603–D610, 2009.

[44] A. Mardinoglu and J. Nielsen, “New paradigms for metabolic modeling of human cells,” *Current Opinion in Biotechnology*, vol. 34, pp. 91–97, 2015.